

Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study – CORRIGENDUM


Corrigendum

Cite this article: Correll CU, Findling RL, Tocco M, Pikalov A, Deng L, and Goldman R (2022). Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study – CORRIGENDUM. *CNS Spectrums* 27(1), 129 <https://doi.org/10.1017/S1092852921000511>

Christoph U. Correll, Robert L. Findling, Michael Tocco, Andrei Pikalov, Ling Deng and Robert Goldman

DOI: 10.1017/S1092852920001893. Published by Cambridge University Press, 09 December 2020.

In the above article¹, Figure 4 has been updated with the following:



Reference

1. Correll, C., Findling, R., Tocco, M., Pikalov, A., Deng, L., & Goldman, R. (2020). Safety and effectiveness of lurasidone in adolescents with schizophrenia: Results of a 2-year, open-label extension study. *CNS Spectrums*, 1–11. doi:10.1017/S1092852920001893